Axovant Sciences Ltd (NYSE:AXON) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, October 17th.
AXON has been the subject of a number of other reports. Cowen and Company restated an “outperform” rating and issued a $30.00 price objective on shares of Axovant Sciences in a report on Wednesday, June 21st. Jefferies Group LLC initiated coverage on Axovant Sciences in a report on Monday, July 10th. They set a “buy” rating and a $40.00 price target for the company. Zacks Investment Research downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Evercore ISI initiated coverage on Axovant Sciences in a research note on Friday, September 8th. They issued an “outperform” rating and a $30.00 target price for the company. Finally, Chardan Capital restated a “sell” rating and issued a $8.00 target price on shares of Axovant Sciences in a research note on Thursday, September 14th. Four research analysts have rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $14.13.
Shares of Axovant Sciences (NYSE AXON) traded up $0.05 during midday trading on Tuesday, reaching $5.31. 616,079 shares of the company traded hands, compared to its average volume of 3,550,000. The company has a current ratio of 6.01, a quick ratio of 6.01 and a debt-to-equity ratio of 0.25. Axovant Sciences has a twelve month low of $4.60 and a twelve month high of $27.98.
Axovant Sciences (NYSE:AXON) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.12).
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/axovant-sciences-ltd-axon-rating-lowered-to-sell-at-bidaskclub/1721173.html.
Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE grew its holdings in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 2,072 shares during the period. Legal & General Group Plc grew its holdings in Axovant Sciences by 20.2% in the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 1,168 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in Axovant Sciences in the first quarter worth about $219,000. American International Group Inc. grew its holdings in Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 998 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Axovant Sciences by 38.5% in the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 2,789 shares during the period.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with our FREE daily email newsletter.